TCBIOTexas Capital Bancshares, Inc.
The schedule
- Thu22Oct
Q3 2026 earnings release focusing on organic deposit stability and cost control.
- Tue9Feb
Q4 2026 earnings release evaluating loan book quality and year-end liquidity buffers.
- Thu22Apr
Q1 2027 earnings release monitoring commercial loan origination growth and asset quality.
- Wed16Jun
Mid-year FOMC meeting and assessment of sector-wide deposit beta and NIM sustainability.
- Thu22Jul
Q2 2027 earnings release serving as a mid-year check on core banking earnings power.
Past
- Wed16Sep
FOMC policy path decisions impacting regional bank yield curves and net interest margins.
- Thu23Jul
Actual outcome: Bear · $20.36 at outcome
TCBIO reported Q2 2026 earnings with an EPS of $2.14, exactly meeting analyst estimates. While the stock saw a marginal 0.7% gain following the release, it ultimately closed at $20.47, breaching the bear floor of $20.69 as the in-line results lacked the upside surprise or forward catalysts needed to drive a meaningful rally.